$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Female Contraception - Pipeline Review, H1 2017
[Report Updated: 30-06-2017]

Published by Global Markets Direct: 30 Jun 2017 | 100108 | In Stock
Related Topics: Healthcare , Women's Health

Introduction

Female Contraception - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2017, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 3, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Female Contraception - Pipeline Review, H1 2017 [Report Updated: 30-06-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Female Contraception - Overview

    Female Contraception - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Female Contraception - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Female Contraception - Companies Involved in Therapeutics Development

    Addex Therapeutics Ltd

    Agile Therapeutics Inc

    Bayer AG

    Evofem Inc

    Hervana Ltd

    Mithra Pharmaceuticals SA

    Orbis Biosciences Inc

    Teva Pharmaceutical Industries Ltd

    Viramal Ltd

    Female Contraception - Drug Profiles

    (anastrozole + levonorgestrel) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (dienogest + ethinyl estradiol) PR - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (drospirenone + estetrol) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    (estradiol acetate + segesterone acetate) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ADX-68693 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AG-200 ER - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AG-200 SP - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AG-20015 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AG-890 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Amphora - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BAY-1007626 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    drospirenone - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Drug for Female Contraception - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    EC-508 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Estetrol - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    etonogestrel ER - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    EVE-106 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    LJ-102 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody Conjugates for Female Contraception - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NOV-1003 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PPCM - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    S-003296 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    S-0101255 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule 2 for Fertility Control - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule for Female Contraception - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptides for Female Contraception - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TV-46046 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Female Contraception - Dormant Projects

    Female Contraception - Discontinued Products

    Female Contraception - Product Development Milestones

    Featured News & Press Releases

    Jun 27, 2017: Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla

    Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal

    Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study

    May 12, 2017: Mithra to Initiate PK Study for Estelle

    May 06, 2017: Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla at ACOG 2017

    May 03, 2017: Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists

    Apr 27, 2017: Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Womens Health

    Apr 11, 2017: Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA

    Mar 16, 2017: Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference

    Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study

    Jan 18, 2017: Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive

    Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial

    Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient

    Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693

    Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

100108 | GMDHC9489IDB

Number of Pages

83

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Female Contraception - Pipeline Review, H2 2016
Female Contraception - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical ...
30 Dec 2016 by Global Markets Direct USD $2,000 More Info
Female Sexual Dysfunction - Pipeline Review, H2 2016
Female Sexual Dysfunction - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceut...
21 Dec 2016 by Global Markets Direct USD $2,000 More Info
The Female Health Company : Consumer Packaged Goods - Company Profile, SWOT and Financial Analysis
SummaryCanadean's "The Female Health Company : Consumer Packaged Goods - Company Profile, SWOT and F...
10 Nov 2016 by Canadean USD $125 More Info
The Female Health Company : Consumer Packaged Goods - Company Profile, SWOT and Financial Analysis
SummaryCanadean's "The Female Health Company : Consumer Packaged Goods - Company Profile, SWOT and F...
10 Nov 2016 by Canadean USD $125 More Info
Intimate Wear Market by Gender (Female and Male), Age Group (13–17, 18–35, 36 and above), Price (Luxury, Super premium, Premium, Medium, Economy, and Low) and Distribution Channel (Retail, Street markets, Specialized chains, Mass market, Variety stores, Department stores, and Other) - Global Opportunity Analysis and Industry Forecasts, 2014-2022
As intimate wear or apparels are worn as second layer of clothes, it is also referred as second skin...
01 Oct 2016 by Allied Market Research USD $4,740 More Info
Compression Wear and Shapewear Market by Product Type (Compression Wear and Shapewear), Application (Performance & Recovery and Body Shaping & Lifestyle), Distribution Channel (Multi-Retail stores, Specialty Stores, and Online Channels), Gender (Male and Female) - Global Opportunity Analysis and Industry Forecasts, 2014-2022
Compression wear and shapewear are close fitted apparels, designed to mold the body to a certain sha...
01 Oct 2016 by Allied Market Research USD $4,740 More Info
Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015
Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial ...
04 Dec 2015 by Global Data USD $2,500 More Info
Female Hypoactive Sexual Desire Disorder Global Clinical Trials Review, H2, 2015
Female Hypoactive Sexual Desire Disorder Global Clinical Trials Review, H2, 2015SummaryGlobalData's ...
04 Dec 2015 by Global Data USD $2,500 More Info
North American Intrauterine Contraceptive Devices (IUCD) Market by Type (Female Contraceptive devices, Male Contraceptive devices) - Forecast to 2019
The North America intrauterine contraceptive devices market is estimated to grow at a CAGR of 0.3% f...
02 Feb 2015 by MicroMarketMonitor USD $2,650 More Info
North American Intrauterine Contraceptive Devices (IUCD) Market by Type (Female Contraceptive devices, Male Contraceptive devices) - Forecast to 2019
The North America intrauterine contraceptive devices market is estimated to grow at a CAGR of 0.3% f...
02 Feb 2015 by MarketsandMarkets USD $2,650 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Female Contraception - Pipeline Review, H1 2017 [Report Updated: 30-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)